MCDS-Therapy Repurposing of carbamazepine for treatment of skeletal dysplasia

Summary

Genetic skeletal diseases (GSDs) are an extremely diverse and complex group of rare genetic diseases that affect the development the skeleton. There are more than 450 unique and well-characterised phenotypes that range in severity from relatively mild to severe and lethal forms. Although individually rare, as a group of related genetic skeletal diseases, GSDs have an overall prevalence of at least 1 per 4,000 children, which extrapolates to a minimum of 225,000 people in the 27 member states and candidate countries of the EU. This burden in pain and disability leads to poor quality of life and high healthcare costs.
Metaphyseal chondrodysplasia, type Schmid (MCDS) results from mutations in collagen X and affects

Resources Show all and search (8)

Unfold all

Fold all

More information & hyperlinks

Web resources:	https://cordis.europa.eu/project/id/754825
Start date:	01-12-2017
End date:	31-05-2024
Total budget - Public funding:	5 697 390,00 Euro - 5 697 390,00 Euro